Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dapagliflozin Suppresses Hepcidin And Increases Erythropoiesis
Husam Ghanim, Sanaa Abuaysheh, Jeanne Hejna, et al.
The Journal of Clinical Endocrinology & Metabolism (2020) Vol. 105, Iss. 4, pp. e1056-e1063
Open Access | Times Cited: 154

Showing 76-100 of 154 citing articles:

Myocardial Infarction
Mukesh Nandave
(2024), pp. 249-318
Closed Access | Times Cited: 3
Sodium-glucose co-transporter-2 inhibitors: peculiar “hybrid” diuretics that protect from target organ damage and cardiovascular events
Riccardo Sarzani, Federico Giulietti, Chiara Di Pentima, et al.
Nutrition Metabolism and Cardiovascular Diseases (2020) Vol. 30, Iss. 10, pp. 1622-1632
Open Access | Times Cited: 22
SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms
Yali Zhang, Yufeng He, Siqi Liu, et al.
American Journal of Cardiovascular Drugs (2023) Vol. 23, Iss. 6, pp. 641-662
Closed Access | Times Cited: 8
Sodium–Glucose Transporter 2 (SGLT2) Inhibitors and Iron Deficiency in Heart Failure and Chronic Kidney Disease: A Literature Review
Maria Tziastoudi, Georgios Pissas, Spyridon Golfinopoulos, et al.
Life (2023) Vol. 13, Iss. 12, pp. 2338-2338
Open Access | Times Cited: 8
Mediators between canagliflozin and renoprotection vary depending on patient characteristics: Insights from the CREDENCE trial
Yohei Doi, Takayuki Hamano, Satoshi Yamaguchi, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2944-2953
Open Access | Times Cited: 7
Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas
Aleix Cases, Secundino Cigarrán, José Luis Górriz, et al.
Nefrología (2023) Vol. 44, Iss. 2, pp. 165-172
Open Access | Times Cited: 7
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient
Paolo Severino, Andrea D’Amato, Silvia Prosperi, et al.
Heart Failure Reviews (2021) Vol. 28, Iss. 3, pp. 709-721
Open Access | Times Cited: 18
Sodium‐glucose cotransporter 2 inhibitor effects on heart failure hospitalization and cardiac function: systematic review
Roy Rasalam, J. Atherton, Gary Deed, et al.
ESC Heart Failure (2021) Vol. 8, Iss. 5, pp. 4093-4118
Open Access | Times Cited: 16
The Pathophysiological Basis of Diabetic Kidney Protection by Inhibition of SGLT2 and SGLT1
Yuji Oe, Volker Vallon
Kidney and Dialysis (2022) Vol. 2, Iss. 2, pp. 349-368
Open Access | Times Cited: 12
Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia
Takeshi Osonoi, Shinichiro Shirabe, Miyoko Saito, et al.
Diabetes Metabolic Syndrome and Obesity (2023) Vol. Volume 16, pp. 1799-1808
Open Access | Times Cited: 7
The treatment of chronic anemia in heart failure: a global approach
Vittorio Emanuele Bianchi, Stephan von Haehling
Clinical Research in Cardiology (2023) Vol. 113, Iss. 8, pp. 1117-1136
Closed Access | Times Cited: 7
Effects of SGLT2 Inhibitors with and without Metformin in High-Risk, Treatment-Naïve Patients with Diabetes
Chen‐Yu Huang, Jen‐Kuang Lee
Journal of Clinical Medicine (2024) Vol. 13, Iss. 5, pp. 1387-1387
Open Access | Times Cited: 2
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance
Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, et al.
Cardiovascular Diabetology (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 2
Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy
Aidar R. Gosmanov, Darren E. Gemoets, K Schumacher
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 10, pp. 2615-2621
Closed Access | Times Cited: 2
Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Angelica Cersosimo, Andrea Drera, Marianna Adamo, et al.
Kidney and Dialysis (2024) Vol. 4, Iss. 4, pp. 184-202
Open Access | Times Cited: 2
Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
Jay B. Wish
Kidney International Reports (2021) Vol. 6, Iss. 10, pp. 2540-2553
Open Access | Times Cited: 16
Anemia of chronic diseases: current state of the problem and perspectives
Olga Iu. Mironova, Alexandr S. Panferov
Terapevticheskii arkhiv (2023) Vol. 94, Iss. 12, pp. 1349-1354
Open Access | Times Cited: 6
The effects of empagliflozin on measured glomerular filtration rate and estimated extracellular and plasma volumes in patients with type 2 diabetes
Mikkel Jürgens, Morten Schou, Philip Hasbak, et al.
Diabetes Obesity and Metabolism (2023) Vol. 25, Iss. 10, pp. 2888-2896
Open Access | Times Cited: 6
Sodium–glucose co-transporter-2 inhibitor use and erythrocytosis: assessment of risk and need for referral to haematology
Naseema Gangat, Ayalew Tefferi
Nephrology Dialysis Transplantation (2023) Vol. 38, Iss. 12, pp. 2670-2672
Open Access | Times Cited: 6
Marked erythrocytosis during treatment with sodium glucose cotransporter-2 inhibitors-report of two cases
Ritesh Gupta, Aanchal Gupta, Mitu Shrikhande, et al.
Diabetes Research and Clinical Practice (2020) Vol. 162, pp. 108127-108127
Closed Access | Times Cited: 16
Alleviation of functional iron deficiency by SGLT2 inhibition in patients with type 2 diabetes
Milton Packer
Diabetes Obesity and Metabolism (2022) Vol. 25, Iss. 5, pp. 1143-1146
Closed Access | Times Cited: 9
Short-term Changes in Hemoglobin and Changes in Functional Status, Quality of Life and Natriuretic Peptides After Initiation of Dapagliflozin in Heart Failure With Reduced Ejection Fraction
Miguel Lorenzo, Gema Miñana, Patricia Palau, et al.
Journal of Cardiac Failure (2023) Vol. 29, Iss. 5, pp. 849-854
Closed Access | Times Cited: 5
Effectiveness and Tolerability of the Intensification of Canagliflozin Dose from 100 mg to 300 mg Daily in Patients with Type 2 Diabetes in Real Life: The INTENSIFY Study
Juan José Gorgojo Martínez, PABLO J. FERREIRA-OCAMPO, Alba Galdón Sanz-Pastor, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4248-4248
Open Access | Times Cited: 5
Sodium-Glucose Cotransporter-2 Inhibitors and Loop Diuretics for Heart Failure
Justin L. Grodin, W.H. Wilson Tang
Circulation (2020) Vol. 142, Iss. 11, pp. 1055-1058
Open Access | Times Cited: 14
Analysis of time-dependent alterations of parameters related to erythrocytes after ipragliflozin initiation
Tomoko Yamada, Kazuhiko Sakaguchi, Yuko Okada, et al.
Diabetology International (2020) Vol. 12, Iss. 2, pp. 197-206
Open Access | Times Cited: 13

Scroll to top